新华社记者司源 孙毅 "我们不仅是来救治病人的，更要留下带不走的能力。"杨萍说。医疗队通过病例讨论、手术演示、现场 教学等方式，提高当地医生在创伤急救、骨折复位、术后康复等方面的独立操作水平，力求将先进经验 真正"扎根"在贝宁土地上。 通讯｜不仅救治病人 更要留下能力——中国第27批援贝宁医疗队纪实 当杨萍医生再次走进重症监护室时，45岁的病人拉韦·贝亚特丽斯已经恢复自主呼吸，生命体征平稳， 正安静接受护理。这名曾被认为几无生还可能的患者，顽强地挺过了最危险的关口。"她真的挺过来 了！"谈到当时的情景，中国第27批援贝宁医疗队队长、外科主任医师杨萍仍激动不已。 这是一名中年女性患者，此前接受腹膜炎及阑尾切除术后突发严重并发症，被紧急转至杨萍所在的贝宁 西南部洛科萨市的莫诺和库福省中心医院。在急诊科会诊时，杨萍发现患者腹腔感染严重，合并肠瘘、 腹壁切口组织大片坏死，生存希望渺茫。尽管如此，她仍在患者家属全力配合下，带领团队实施了紧急 剖腹探查、结肠造瘘、清创缝合等手术。 奇迹在两周后出现。病人恢复清醒、生命体征稳定，之后康复出院，并于术后半年再次接受结肠造瘘还 纳及消化道重建手术，最终成功回归正常生活。这场生死 ...

当前医保支出多以仿药和中药为主，创新药的比例仅为3%，未来创新药商保支付的空间巨大。 中国生物医药快速发展的同时，机遇与挑战并存。面对技术迭代的瞬息万变、资本与产业需求的适配难 题，以及全球竞争格局下的协同困境，生物医药参与方仍需进一步探索破局之道。 在近期举办的陆家嘴金融沙龙上，多位产业界、投资界、学术界专家以"聚势·破局：生物医药产业与资 本的协同发展"为主题进行了深入讨论，分析了中国生物医药在国际所处水平、面临的机遇与挑战，以 及资本的赋能路径。 嘉宾一致认为，国外公司对中国生物医药质量的认可度正在逐步提升，生物医药产业跃升还需多方协 同，比如：政府优化审评审批与支付政策，资本提供长期耐心支持，企业提升全球运营能力，科研机构 强化源头创新。 中国生物技术产业危与机并存 相较美国、欧洲等发达国家，中国在生命科学领域的基础科研处在怎样的水平，中国做Biotech（生物 技术）面临哪些机遇与挑战？在中国创新药快速发展的背景下，这些问题成为市场的关注点。 针对地缘政治和美国药价政策可能对跨国药企与中国药企合作产生的影响，杨樱称，这是一个复杂的问 题，"目前中国和美国的药价存在巨大差异，而美国政府提出的最惠国待遇 ...

Core Viewpoint - The new healthcare policy aims to enhance the accessibility of innovative drugs through the establishment of a commercial insurance innovation drug directory, which is expected to include around 20 to 30 new drugs, thereby improving the overall insurance coverage for patients [6][9]. Group 1: Policy Changes - The National Healthcare Security Administration (NHSA) has released a series of documents outlining the adjustments to the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug directories, as well as the commercial health insurance innovation drug directory [2][4]. - The new policy emphasizes a collaborative negotiation mechanism for the commercial insurance innovation drug directory, differing from the basic insurance directory's negotiation process [6][8]. Group 2: Market Impact - The introduction of the commercial insurance innovation drug directory is expected to allow insurance companies to negotiate prices with pharmaceutical companies, leading to lower prices compared to existing market rates [6][8]. - This policy is anticipated to expand the coverage of commercial insurance and reduce operational costs for insurance companies, ultimately benefiting patients by increasing their access to innovative drugs [6][9]. Group 3: Implementation and Future Outlook - The NHSA will begin accepting applications from eligible companies for the new drug directory starting from July 20, 2023, indicating that the preparation for the 2025 adjustments is nearly complete [9]. - The dynamic nature of the directory, which will be updated annually, suggests that more innovative drugs may be included in short-term health insurance plans in the future, providing more options for the public [8][9].

金十数据7月10日讯，中共中央政治局委员、国务院副总理刘国中10日到北京大学医学部调研医药创新 发展工作。他强调，要强化协同攻关和政策落实，加强医药领域基础研究和科技创新能力建设，积极支 持创新药和医疗器械加快发展，为推进健康中国建设提供有力支撑。要坚定信心，充分发挥我国在产业 体系、发展环境等方面优势，聚焦重点难点问题，有力推动医药创新和产业高质量发展。要加强产学研 深度融合，鼓励企业、高校、科研机构与医疗机构联合攻关，提高医药科技创新水平，在药物、疫苗和 医疗器械研发方面取得更多突破性成果。 （新华社） 刘国中：加快医药创新发展 更好保障人民健康 ...

南方财经.21世纪经济报道记者围绕今年医保目录新政，深入分析政策设计思路，解读此次释放的政策 信号对市场的影响。商保创新药侧重协商定价 相关文件甫一发布，最受市场关注的当数新增商保创新药目录。对此，一位医保业内核心专家对记者分 析，医保部门相当于首次给了市场一份创新药支持清单，可能会有二三十种药。将弥补基本医保目录的 空白，整体提高现有保障水平。 21世纪经济报道记者贺佳雯北京报道 7月10日晚，国家医保局正式发布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健 康保险创新药品目录调整工作方案》《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业 健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。 有别于基本医保目录谈判机制，值得注意的是，商保创新药目录更侧重协商机制。从政策设计层面考 虑，体现了强度上的差异。 事实上，此前商保公司鲜少有机会和能力，与医药企业"砍价"。"此次医保搭台，以商保公司为主。"该 专家说，具体价格怎么谈，还是看商保公司和药企协商。通过医保、保险公司和医药企业三方协商，对 创新药评估一个价格，这个价格肯定比原有市场价低。这对商保 ...

辟谣。 近日，一篇题为《7月起医保新调整，"个人账户"将全部取消，卡内余额转哪里去?》的自媒体文章引起较 多关注。文中宣称"从医保局内部人士处获悉，全国医保个人账户改革已进入关键阶段""自2025年7月1日 起，全国范围内分步推进医保个人账户改革，最终目标是取消现行个人账户模式"。 对此，中国互联网联合辟谣平台向有关部门查证得知，相关文章中"个人账户将全部取消""全国范围内全面 取消个人账户，所有医保缴费全部进入统筹基金，建立全国统一的医疗保障积分系统"等内容纯属谣言。 事实上，按照中央"改革职工基本医疗保险个人账户，建立健全门诊共济保障机制"部署和《关于建立健全 职工基本医疗保险门诊共济保障机制的指导意见》（国办发【2021】14号）要求，目前医保改革正顺利 推进，多数地区已顺利完成相关工作。此次改革是在不增加社会和个人额外负担的前提下，建立职工医保 普通门诊统筹，不存在"取消职工个人账户"。 值得注意的是，此类谣言并非首次出现。 早在2023年10月，国家医疗保障局办公室和中国互联网联合辟 谣平台就曾针对"取消职工医保个人账户"的谣言进行过专门辟谣。然而，时隔一年多，类似虚假信息再次 出现。谣言故意歪曲医 ...

Group 1 - The company expects to achieve a net profit attributable to shareholders of approximately 8.561 billion yuan, representing a year-on-year increase of about 101.92% [1] - For the first half of 2025, the company anticipates total revenue of approximately 20.799 billion yuan, a year-on-year growth of about 20.64%, with revenue from continuing operations increasing by approximately 24.24% [1] - The significant growth in net profit is partly attributed to investment gains from the sale of shares in an associate company, with expected gains of about 3.21 billion yuan from the sale of WuXi AppTec shares [1] Group 2 - Excluding certain impacts, the company expects an adjusted net profit of approximately 6.315 billion yuan, reflecting a year-on-year increase of about 44.43% [3] - The company projects a net profit attributable to shareholders, excluding non-recurring gains and losses, of approximately 5.582 billion yuan, which is a year-on-year growth of about 26.47% [3] - The biopharmaceutical sector has shown signs of recovery in 2025, driven by a surge in external authorization transactions, which may benefit the contract research organization (CRO) and contract development and manufacturing organization (CDMO) segments [3] Group 3 - The company previously projected that revenue from continuing operations would return to double-digit growth in 2025, with a year-on-year increase of 10% to 15% [4] - Overall revenue for 2025 is expected to reach between 41.5 billion and 43 billion yuan, representing a year-on-year growth of 5.76% to 9.6% compared to 2024 [4] - Achieving these targets would mean that the company's total revenue would surpass the peak revenue achieved in 2023, driven by the commercialization of COVID-19 [4]

Core Viewpoint - The Beijing Municipal Government has issued the "Beijing Special Action Plan for Deepening Reform and Boosting Consumption," which includes 24 measures aimed at enhancing consumption quality and optimizing the consumption environment, with a target of achieving an average annual growth of around 5% in total market consumption by 2030 [1] Group 1: Housing Consumption Policies - The plan introduces a new policy allowing individuals to withdraw housing provident fund for down payments while simultaneously applying for housing loans, which is expected to lower the threshold for home purchases and alleviate financial pressure on buyers [2] - The proposed "mortgage transfer" policy aims to simplify the second-hand housing transaction process, reducing transaction time and costs, thereby increasing market liquidity [2][3] Group 2: Automotive Consumption Policies - The action plan emphasizes the need to optimize small car indicator allocation to better meet family vehicle needs and expand the automotive aftermarket, including modifications and rentals [4] - The current situation shows a significant competition for car purchase indicators, with a probability of winning for families at approximately 1% and for individuals at 0.1%, highlighting the need for policy reform [4] Group 3: Service Consumption Enhancement - The plan aims to leverage cultural resources to enhance service consumption, supporting new business models such as online performances and live auctions, which are expected to enrich entertainment consumption [5] - The initiative also focuses on developing health and domestic services, encouraging internet platforms to facilitate better supply-demand matching [5] Group 4: Income Growth Initiatives - The action plan outlines measures to promote reasonable growth in wage income, including adjustments to the minimum wage standards, which currently stand at 2420 yuan per month [6] - The plan also aims to broaden channels for property income and enhance financial services for the elderly, indicating a comprehensive approach to improving residents' financial well-being [6]

绵阳核医疗健康产业园签约28个项目，总投资高达223亿元。 作 者丨 杨婧雪 编辑丨 刘恒涛 图源 丨 midjourney 近期，核医疗赛道的资本动作不断。 5 月 26 日，主攻脑神经、心血管、肿瘤领域方向的核药 CRO/CDMO 服务企业国通新药完成 A+ 轮融资，投资方中不乏国寿股权这样的头部机构。 6 月 9 日，核药企业先通医药向港交所递表； 6 月 10 日，中广核技宣布向全资子公司中广核医疗科技（绵阳）有限公司增资 5 亿元，投向质子医疗 研发。 这三家企业有一个共同之处 ——它们都是四川绵阳的企业，均已入驻绵阳核医疗健康产业园。 在绵阳，核医疗产业集群正在悄然成形。绵阳核医疗产业链已引入一家国家链主企业， 16 家链上重 点企业。绵阳核医疗健康产业园已签约 28 个项目，总投资将高达 223 亿元。 为什么核医疗产业资本和企业如此看好绵阳？ 先进放疗技术聚集 绵阳领跑核医疗产业 坐落于绵阳游仙区的 核医疗健康产业园 ，聚集了一批放疗黑科技的设备。 今年 5 月，来自园区企业中玖闪光的两台放疗设备—— X-Flash 与 e-Flash ，亮相西博会 ， 引发 轰动。 图源： 绵阳市经济合作局 ...

Core Points - The article announces the upcoming Second Global Medical Technology Conference scheduled for July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, expecting around 500 attendees [3][8] - The conference will feature various discussions on topics such as AI in medical devices, wearable brain-machine interfaces, and trends in the medical device industry for 2025 [4] Group 1 - The conference is organized by SYMedTech and the Zhongguancun Alliance for New Life Sciences [3] - Collaborating organizations include Qidi Star, He Yuan Technology Incubator, and Zhongguancun Science City CGT Industry Incubator [2] - The agenda includes presentations from industry experts on innovative medical technologies and investment strategies [4] Group 2 - The event will also include a roundtable discussion focusing on multi-modal data infrastructure and AI applications in medicine [4] - Other topics of discussion will cover the development of the pulsed electric field ablation industry and AI's role in reshaping brain health [4] - The article provides a registration link with a promotional offer for attendees [8]